# CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies

> **NCT04605666** · PHASE2 · COMPLETED · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 77 (actual)

## Conditions studied

- B Cell Leukemia
- B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CD19-CAR-T2 Cells

## Key facts

- **NCT ID:** NCT04605666
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04605666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04605666, "CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04605666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*